Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Dose Oral Bioequivalence Study of Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) and Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) in Healthy Adult Human Participants Under Fasting Conditions.

NCT07691190 is registered in ClinicalTrials.gov with Humanis Saglık Anonim Sirketi as lead sponsor.

NCT NCT07691190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07691190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Dose Oral Bioequivalence Study of Cariprazine 1.5 mg Hard Capsules (1.5 mg Cariprazine Hydrochloride) and Reagila® 1,5 mg Hartkapseln (Hard Capsules) (Cariprazine) in Healthy Adult Human Participants Under Fasting Conditions.
Lead sponsor
Humanis Saglık Anonim Sirketi
Phase
Phase 1
Overall status
Completed
Start date
March 5, 2026
Completion date
June 26, 2026
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia 1 (disorder)